May 20, 2020 / 11:47 AM / in 13 days

BRIEF-Surface Oncology And Merck To Collaborate On Immuno-Oncology Study Evaluating Srf617, Targeting CD39 In Combination With Keytruda In Solid Tumor Patients

May 20 (Reuters) - Surface Oncology Inc:

* SURFACE ONCOLOGY AND MERCK TO COLLABORATE ON IMMUNO-ONCOLOGY STUDY EVALUATING SRF617, TARGETING CD39 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN SOLID TUMOR PATIENTS

* SURFACE ONCOLOGY INC - COMBINATION WILL BE STUDIED AS A COMPONENT OF FIRST-IN-HUMAN PHASE 1/1B STUDY OF SRF617 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below